Guangdong issues first prescription for cancer electric field treatment

Guangdong issued the first prescription for the treatment of cancer electric field Zhong XinXinhua Guangzhou, June 30 (Cai Minxuan) Zhongshan University Cancer Prevention and Control Center on the 30th issued the first prescription for cancer electric field treatment in GuangdongMu Yongxuan, director of neurosurgery at the center, said that over the years, the treatment of glioblastoma has been slow, and the treatment of tumor electric field has been proven to be effective and safe in the treatment of glioblastoma by large-scale international clinical trialsthe patient's family member MrWang (pseudonym) said that late last year, the patient suddenly emergency hospital surgery, after pathological genetic testing confirmed as glioblastoma"In fact, it has been learned that tumor electric field treatment can be used in Hong Kong, but the outbreak relationship can not go to Hong Kong, can now be directly in the Mainland for treatment." MrWang saidGuangdong issued the first cancer electric field treatment prescription Zhong Xinglioblastoma is the highest incidence of primary malignant central nervous system tumors, high degree of malignancy, rapid growth, short course, after surgery easy to relapse and high disability, patients clinical prognosis is very poor, median survival period is only 15 months, recurrence rate is close to 100%, is considered neurosurgical treatment of one of the most difficult difficult tumorsSaid that tumor electric field therapy is a tumor treatment that uses a specific electric field frequency to interfere with cell division, inhibit tumor growth and kill tumor cells affected by electric field, by interfering with tumor cell filament, inhibiting tumor growth and death of cancer cells affected by electric fieldThe most common adverse reaction is mild to moderate skin irritationOn May 13 this year, the State Drug Administration approved the treatment of tumor electric field for the treatment of newly diagnosed glioblastoma patients in conjunction with dimomine, as well as for patients with recurrent glioblastoma as a single therapyInternational Phase III Multicenter Clinical Study EF-14 confirmed that in newly diagnosed glioblastoma patients, the five-year total survival rate of patients receiving tumor electro-field therapy and TMZ in combination with tMZ increased more than twice, from 5% to 13%, and the median total survival was extended from 16 months to 20.9 monthsMu Yongxuan introduced that in China, each year more than 45,000 patients were diagnosed with glioblastoma, tumor electric field therapy market breakthrough 15 years of domestic glioblastoma treatment dilemma, "surgery and chemotherapy and tumor electric field treatment" has become the new standard treatment planthe same day, the first charitable assistance program for patients with glioblastoma initiated by the China Primary Health Care Foundation was launched, with Reding Pharmaceuticals providing assistance to the China Primary Health Care Foundation for tumor electro-field treatment patches, which will be available to eligible low-income patients and low-income patients from June 2020(Complete) Source: China News Network